The Role Of SGLT-1 Inhibitors in Weight Management for Diabetic Patients

KHASHAYAR MOHAMMADI
Wye Valley NHS Trust

Abstract- ***Sodium glucose co-transporter-1 inhibitors were initially used to treat type-2 diabetes but have now emerged as potential candidates in the field of weight management in diabetic patients. The inhibitors when blocking the SGLT-1 transporter in the jejunum and ileum decrease the absorption of glucose conversely, stimulation of a higher excretion of glucose via urine. When considered an extremely important player in the glycemic control, it is equally important in beings an agent of weight reduction. Weight reduction is vital for metabolic control and minimization of complications since obesity is one of the known comorbidities affecting type-2 diabetic patients. Weight loss elicited by SGLT-1 inhibitors is believed to involve mechanisms other than glucose regulation, including appetite suppression and elevation of insulin sensitivity. This article will discuss how SGLT-1 inhibitors pharmacologically impact body weight and put in perspective mechanisms that should be made pertinent in weight loss for diabetic patients in clinical practice. Further, we shed light on the safety aspect of SGLT-1 inhibitors and equip readers with inputs for consideration with regard to their role in integrated weight management strategies for diabetes care.***

I. INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a chronic disorder characterized by insulin resistance and impaired insulin secretion with an elevation of blood glucose levels. A substantial proportion of those suffering from T2DM also are overweight or obese, thus increasing insulin resistance and the possibility of cardiovascular complications, hypertension, and dyslipidemia. Accordingly, weight management is an important interface of comprehensive diabetic care. With more options for pharmacotherapy available for glycemic control, there are relatively fewer alternatives with meaningful weight-reduction benefits.

Sodium-glucose cotransporter inhibitors have captured the limelight for dual actions of glycemic control and weight reduction in recent years. Already widely used and approved in many countries for the management of T2DM, SGLT-2 inhibitors offer modest weight loss as a secondary effect. The SGLT-1 inhibitors, or dual SGLT-1/2 inhibitors, represent a novel treatment that has a more obvious influence on intestinal glucose absorption and could, therefore, have a larger impact on postprandial glycemia and body weight.

SGLT1 is mainly expressed in the small intestine, where it helps in the transport of glucose and galactose from the lumen into enterocytes. Inhibition of SGLT1 reduces glucose absorption, slows postprandial glucose excursions, and possibly increases satiety through modulation of gut hormones. The pharmacological modality The role of caloric deficit followed by weight loss could be an added feature, in addition to blood glucose regulation. This paper throws light on the emerging role of SGLT-1 inhibitors in weight management among diabetic patients, exploring their mechanism of action, clinical evidence, and potential for tackling the double burden of hyperglycemia and obesity.

II. MECHANISM OF ACTION OF SGLT-1 INHIBITORS

The sodium-glucose co-transporter 1 (SGLT-1) is a specific glucose transporter that resides in the brush-border membrane of the small intestine, with a minor population being present in the renal proximal tubules, heart, and brain. It is responsible for actively absorbing glucose and galactose from the intestinal lumen into enterocytes, particularly after the intake of carbohydrate-rich meals. With SGLT-1, there is active absorption of glucose and galactose from the intestinal lumen into enterocytes, especially after carbohydrate-rich meals. When SGLT-1 is inhibited, this process is blocked, thus decreasing the postprandial spike in plasma glucose and the overall calorie intake.The class of SGLT-1 inhibitors elicits their therapeutics by competitively binding to the SGLT-1 transporter, thereby hindering the co-transport of glucose and sodium ions into intestinal epithelial cells. Delayed and reduced intestinal glucose absorption ensue, with an increasing quantity of glucose reaching the distal parts of the intestine. Incretin hormone secretion in the lower gut is therefore abnormally increased with the sugars present there, mainly GLP-1 and PYY, both known for appetite suppression and enhanced insulin sensitivity.

Inhibiting SGLT-1 mainly acts at the intestinal level, with some renal effect, especially dual SGLT-1/2 inhibition by sotagliflozin. SGLT-2 reabsorbs almost 90% of the filtered glucose load through the kidneys, while SGLT-1 reabsorbs the rest: dual inhibition thereof will instead increase urinary glucose excretion, thus improving glycemic control. It also causes mild osmotic diuresis, which may contribute to lowering The combined intestinal and renal mechanisms provide a synergistic effect: reduced dietary glucose absorption limits caloric intake, while increased urinary glucose excretion promotes energy loss. Together, these effects support the potential of SGLT-1 inhibitors as a therapeutic strategy for not only glycemic control but also weight management in type 2 diabetes patients.



III. EFFECTS ON WEIGHT MANAGEMENT

Weight loss is one aspect of the management in type 2 diabetes, as excess body weight worsens insulin resistance and facilitates disease progression. Unique among SGLT-1 inhibitors is the potential, mainly when combined with SGLT-2 inhibitors, to assist in weight loss among diabetic patients through several complementing physiological effects.Lost calories through diminished glucose absorption in the intestinal mucosa and increased glycosuria are approached as the main avenues of weight reduction. On one hand, the inhibition of SGLT-1 activity in the small intestine diminishes the absorption of glucose, hence calories, into the bloodstream from ingested food. This leaves more glucose to seep down into the colon, a slight caloric deficit that may eventually cause weight loss.

Secondly, apart from the loss of calories, there is an effect on body weight exerted indirectly by altering the gut hormones. Delivery of unabsorbed glucose to the distal gut enhances the secretion of incretins such as GLP-1 and PYY which stimulate satiety and inhibit appetite. Appetite suppression thereby reduces food intake and further facilitates the weight-lowering effect of the drug.The Bt-hyphenated dual SGLT-1/2 inhibitors induce slight but yet still clinically important weight reduction. Patients experience weight reduction of about 2 to 3 kg in 24-52 weeks, depending upon baseline weight, dose, and adherence. From this point of view, these weight-reducing drugs find greatest use in the overweight or obese diabetic group that struggles to remain weight-free in commonly used lifestyle intervention strategies.

Another contributory factor may be mild osmotic diuresis due to glycosuria, which starts off with a water weight loss. This is an early transient phase imparting quick weight loss, which tends to favor adherence and motivation in patients.More importantly, the weight reduction obtained by SGLT-1 inhibition is at least partly accomplished via reduction of fat mass rather than lean body mass, a distinct metabolic advantage. This is contrary to some other antidiabetic therapies that either induce weight gain or at best encourage fluid retention. Briefly, SGLT-1 inhibitors aid weight management through a complex mechanism consisting of decreased intestinal glucose absorption, calorie loss, appetite repression, and hormonal changes. This pharmacology makes them a useful adjunct in the overweight or obese patient with type 2 diabetes.

Weight management continues to pose a challenge in the care of T2DM since a number of antidiabetic agents, insulin and sulfonylureas being a few among them, do cause weight gain. On the contrary, SGLT-1 inhibitors, mostly when given as a dual inhibitor with SGLT-2 inhibitors, show a nice profile by draining calories away from the body and somehow controlling appetite, with weight loss as an outcome. This section examines the physiology, clinical trials, or evidence, and comparative benefits that explain their effects on body weight.

1. Caloric Loss via Glucosuria and Malabsorption

One of the primary mechanisms by which SGLT-1 inhibitors contribute to weight loss is caloric elimination through:

- Inhibition of intestinal glucose absorption (SGLT-1), reducing caloric uptake from ingested carbohydrates.

- In dual inhibitors, SGLT-2 blockade in the proximal renal tubules promotes urinary glucose excretion, leading to additional loss of 200–300 kcal/day.

This dual-site action results in a net negative energy balance, promoting gradual weight loss.

2. Altered Gut Hormone Secretion

SGLT-1 inhibition delays carbohydrate absorption, leading to increased glucose in the distal small intestine and colon. This delayed absorption stimulates the secretion of gut hormones such as:

- GLP-1 (glucagon-like peptide-1): Enhances satiety, delays gastric emptying, and promotes insulin secretion in a glucose-dependent manner. Peptide YY (PYY): Induces satiety and reduces food intake.

  These hormonal changes can suppress appetite and contribute to reduced caloric intake, complementing the effects of energy loss through glycosuria.

3. Decrease in Insulin Requirements

By improving postprandial glycemic control and reducing overall glucose load, SGLT-1 inhibitors may allow for:

- Lower doses of exogenous insulin or insulin secretagogues.
- Reduced insulin-induced lipogenesis, which is a key factor in treatment-related weight gain.

This insulin-sparing effect is particularly valuable in type 2 diabetes patients who are prone to weight gain from insulin therapy.

4. Clinical Evidence of Weight Reduction

- In clinical trials (e.g., inTandem, SCORED), patients treated with sotagliflozin experienced modest but consistent weight loss ranging from 1.5 to 4.0 kg over 24 to 52 weeks.
- Meta-analyses indicate that dual SGLT-1/2 inhibitors produce greater weight loss than SGLT-2 inhibitors alone, possibly due to their additional effects on appetite regulation and postprandial glucose control.
- Importantly, weight loss was sustained over time and occurred without major dietary interventions, highlighting the direct pharmacologic effect.

5. Metabolic and Cardiovascular Benefits of Weight Loss

Weight reduction achieved through SGLT-1 inhibition may confer indirect benefits including:

- Improved insulin sensitivity and reduced insulin resistance.
- Decreased hepatic steatosis and improvement in non-alcoholic fatty liver disease (NAFLD).
- Reduced visceral adiposity, a strong risk factor for cardiovascular disease.

These improvements may help slow the progression of T2DM and reduce the burden of metabolic comorbidities.

6. Variability in Weight Loss Response

- Weight loss response may vary depending on baseline BMI, dietary patterns, medication adherence, and gut microbiome composition.
- Some patients may experience plateauing of weight loss after 3–6 months due to compensatory increases in appetite or adaptive metabolic responses.

Summary Table: Weight Management Effects of SGLT-1 Inhibitors

Mechanism	Effect on Weight
Intestinal glucose malabsorption	↓ Caloric absorption
Renal glucose excretion (in dual therapy)	↓ Calories through glycosuria (~200–300 kcal/day)
Gut hormone modulation (↑ GLP-1, PYY)	↑ Satiety, ↓ Appetite
Lower insulin doses	↓ Insulin-induced weight gain
Sustained clinical results	1.5–4.0 kg weight loss over 6–12 months

Summary Table: Weight Management Effects of SGLT-1 Inhibitors

Mechanism	Effect on Weight
Intestinal glucose malabsorption	↓ Caloric absorption
Renal glucose excretion (in dual therapy)	↓ Calories through glycosuria (~200–300 kcal/day)
Gut hormone modulation (↑ GLP-1, PYY)	↑ Satiety, ↓ Appetite
Lower insulin doses	↓ Insulin-induced weight gain
Sustained clinical results	1.5–4.0 kg weight loss over 6–12 months

IV. CLINICAL STUDIES AND EVIDENCE

Increasingly, clinical research supports the benefits of SGLT-1 inhibitors in weight control and glycemic regulation, especially dual SGLT-1/2 inhibitors such as sotagliflozin. While selective SGLT-1 inhibitors remain largely experimental, dual inhibitors have been evaluated in several large-scale, randomized controlled trials. Multiple RCTs, meta-analyses, and real-world studies have rigorously evaluated the efficacy and safety of SGLT-1 inhibitors, especially dual SGLT-1/SGLT-2 inhibitors like sotagliflozin. The studies have shown some benefits in glycemic control, weight management, cardiovascular outcomes, and renal protection, thus providing a well-rounded perspective on the possible role of these drugs in the treatment of diabetes.

1. The inTandem Trials (inTandem1, inTandem2, inTandem3)

- Population: Adults with Type 1 Diabetes Mellitus (T1DM) inadequately controlled on insulin.
- Design: Multicenter, double-blind RCTs evaluating the addition of sotagliflozin to insulin therapy.
- Key findings:
- Significant reductions in HbA1c (~0.3–0.4%) vs. placebo.
- Reduction in postprandial glucose excursions due to delayed intestinal glucose absorption.
- Weight loss of approximately 2–3 kg over 24–52 weeks.
- Increased incidence of diabetic ketoacidosis (DKA), especially at higher doses or in insulin-deficient patients.

Clinical Implication: While effective in T1DM, careful patient selection and education are required due to DKA risk.

2. The SCORED Trial (Sotagliflozin in Patients with Diabetes and CKD)

- Population: Over 10,000 adults with T2DM and chronic kidney disease (CKD).
- Design: Double-blind, placebo-controlled, event-driven cardiovascular outcomes trial.

Key Outcomes:

- 26% reduction in the composite of cardiovascular death, hospitalization for heart failure (HHF), or urgent HF visits.
- Significant reductions in HbA1c, body weight, and systolic blood pressure.
- Consistent benefits across CKD stages, including patients with reduced eGFR (as low as 25 mL/min/1.73 m²).
- Higher incidence of diarrhea and genital mycotic infections, but overall favorable safety.

Clinical Implication: Sotagliflozin provides robust cardiorenal protection even in advanced CKD, where other oral agents are limited.

3. The SOLOIST-WHF Trial (Sotagliflozin in Patients with T2DM after Worsening Heart Failure)

- Population: T2DM patients recently hospitalized for worsening heart failure.
- Design: Multicenter, randomized trial initiated before or shortly after discharge.
- Key Results:
- 33% reduction in total HF events and cardiovascular death.
- Early initiation of sotagliflozin showed benefits within days of discharge.
- Improved outcomes regardless of ejection fraction, suggesting utility in both HFrEF and HFpEF.

Clinical Implication: Dual SGLT-1/2 inhibition can be safely initiated during the vulnerable post-discharge period to prevent readmissions.

4. Meta-Analyses of SGLT-1/2 Inhibitors

- Aggregated data from >20 RCTs indicate:
- HbA1c reduction: ~0.4–0.6% (dose-dependent).
- Weight loss: 2–4 kg over 6–12 months.
- Postprandial glucose reduction is greater than SGLT-2 inhibitors alone, due to intestinal absorption delay.
- Slightly increased incidence of gastrointestinal side effects, especially diarrhea and flatulence, attributed to luminal glucose retention.
- Ketoacidosis risk is primarily observed in T1DM or insulin-deficient patients.

Comparison with SGLT-2 Inhibitors Alone:

Outcome	SGLT-2 Inhibitors	SGLT-1/2 Dual Inhibitors
HbA1c reduction	0.4–0.7%	0.5–0.8%
Weight loss	2–3 kg	2–4 kg
PPG control	Moderate	Strong
GI side effects	Rare	More frequent
DKA risk in T1DM	Present	Slightly higher

5. Real-World Evidence and Observational Studies

- Registries and cohort studies support RCT findings, confirming:
- Durable glycemic control and weight benefits.
- Real-world adherence challenges due to GI tolerability.
- Favorable effects on blood pressure, lipid profile, and quality of life in overweight/obese patients.

Example:

- A European multicenter observational study reported a mean weight reduction of 3.2 kg and a mean HbA1c drop of 0.5% after 6 months of sotagliflozin in T2DM patients, with minimal serious adverse events.

Limitations and Gaps in Current Evidence

- Lack of long-term data (>2 years) for selective SGLT-1 inhibitors alone.
- Limited head-to-head comparisons between SGLT-1 inhibitors and GLP-1 RAs for weight loss.
- Underrepresentation of certain populations (e.g., adolescents, elderly >75 years, ethnic minorities).
- More studies are needed on gut microbiome interaction, insulin resistance modulation, and non-diabetic obesity treatment.

The clinical trial landscape strongly supports the efficacy of SGLT-1 inhibitors, particularly in dual therapy formats, in improving glycemic control, inducing weight loss, and offering cardiorenal protection. However, personalized therapy, careful risk-benefit assessment, and further studies on long-term outcomes are essential to solidify their place in diabetes care algorithms.

V. PATIENT SELECTION AND THERAPEUTIC CONSIDERATIONS

Optimal use of SGLT-1 inhibitors, especially in combination with SGLT-2 inhibition, requires thoughtful patient selection to maximize therapeutic benefits while minimizing risks. Given their dual impact on glycemic control and weight management, these agents may be most appropriate for specific subpopulations within the diabetic community.

1. Ideal Candidates

SGLT-1 inhibitors may be particularly suitable for:

- Overweight or obese type 2 diabetes patients struggling with weight loss despite lifestyle modifications.

- Patients with prominent postprandial hyperglycemia, where delayed intestinal glucose absorption can have a marked impact.
- Individuals at low risk for gastrointestinal intolerance, such as those without pre-existing GI disorders.
- Patients seeking insulin-sparing regimens, especially those at risk of weight gain or hypoglycemia from insulin therapy.

For dual SGLT-1/2 inhibitors, additional ideal characteristics include:

- Mild to moderate renal impairment (where SGLT-2 inhibitors alone may be less effective).
- Cardiometabolic risk factors, as agents like sotagliflozin have shown cardiovascular and renal benefits.

2. Patients Requiring Caution or Exclusion

Caution is advised in the following populations:

- Type 1 diabetes patients, due to elevated risk of euglycemic diabetic ketoacidosis (EDKA); use is not widely approved.
- Individuals with gastrointestinal conditions such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD), where increased luminal glucose may worsen symptoms.
- Elderly patients or those on diuretics, due to risk of dehydration, hypotension, and electrolyte imbalances.
- Patients with a history of frequent genitourinary infections, especially women.

Absolute contraindications may include:

- Severe renal impairment or end-stage renal disease, depending on the agent.
- Active or recurrent ketoacidosis episodes.
- Known hypersensitivity to the drug or its components.

3. Dosing and Titration

- Start low and go slow: Initiating treatment at the lowest effective dose and gradually titrating upward can reduce GI and osmotic side effects.
- Combination with other antidiabetics: Co-administration with insulin or sulfonylureas requires dosage adjustments to avoid hypoglycemia.
- Meal timing: Since SGLT-1 inhibitors affect postprandial glucose, administration with or just before meals is recommended for maximum efficacy.

4. Monitoring and Follow-Up

- Glycemic monitoring: Evaluate HbA1c, fasting, and postprandial glucose regularly.
- Weight and hydration status: Track weight trends and monitor signs of volume depletion, especially in elderly patients.
- Adverse effects: Assess for gastrointestinal symptoms, infections, and signs of ketoacidosis (e.g., abdominal pain, fatigue, nausea).

5. Patient Education

- Inform patients about the expected side effects (especially GI discomfort).
- Emphasize the importance of hydration, especially in warmer climates or during physical activity.

- Educate on ketoacidosis warning signs, even if blood glucose appears normal.



VI. FUTURE DIRECTIONS

As the clinical relevance of SGLT-1 inhibitors continues to emerge, especially in combination with SGLT-2 inhibition, several key research and development pathways are poised to shape their future role in diabetes and metabolic health management.

1. Development of Selective SGLT-1 Inhibitors

Currently, most clinical data stems from dual SGLT-1/2 inhibitors such as sotagliflozin. However, the development of selective SGLT-1 inhibitors may offer a targeted therapeutic approach for patients primarily experiencing postprandial hyperglycemia or those with specific gastrointestinal absorption issues. These agents may allow finer modulation of glucose handling with fewer renal side effects.

2. Expansion to Obesity and Metabolic Syndrome

Given their weight-lowering effects, future trials may explore the use of SGLT-1 inhibitors in:

- Non-diabetic individuals with obesity, particularly where traditional weight-loss agents are contraindicated.
- Patients with metabolic syndrome, where improving insulin sensitivity, weight, and blood pressure could yield synergistic benefits.
- Polycystic ovary syndrome (PCOS) and other endocrine disorders with metabolic components.

3. Combination Therapies and Personalized Medicine

Future treatment models may include:

- Triple-combination therapies, integrating SGLT-1 inhibitors with GLP-1 receptor agonists or DPP-4 inhibitors to target multiple metabolic pathways.
- Personalized medicine approaches, using biomarkers such as postprandial glucose response, gut hormone profiles, or microbiota composition to identify likely responders.

4. Gut Microbiome Interactions

Emerging studies suggest that SGLT-1 inhibition alters the composition of the gut microbiome, which may mediate some of its metabolic benefits or side effects. Future research may explore:

- Whether microbiome profiling can predict tolerability or efficacy.
- How long-term microbiome shifts impact host metabolism, inflammation, and glucose homeostasis.

5. Long-Term Safety and Outcome Studies

Large, long-duration studies are needed to:

- Evaluate the sustainability of weight loss and metabolic improvements.
- Assess potential gastrointestinal and renal effects over several years.
- Establish cardiovascular and renal outcome data specific to selective SGLT-1 inhibition, beyond what is known from dual inhibitors.

6. Novel Delivery Mechanisms

Innovation in drug delivery—such as extended-release oral tablets, intestinal-targeted formulations, or combination pills—could improve:

- Tolerability by minimizing peak drug concentrations in the GI tract.

Adherence, particularly in populations already managing complex medication regimens.

CONCLUSION

Offering a novel, muti-pronged approach to the treatment of diabetes, SGLT-1 inhibitors appear to promise significant clinical translation in glycemic control and weight management- the two most critical and intertwined aspects of metabolic disease. From a glycemic control standpoint, SGLT-1 inhibition allows significant reductions of postprandial glucose excursions by delaying carbohydrate absorption from the lumen of the small intestine. In the setting of enhanced renal glucose excretion by SGLT-2 inhibition, this would be expected to produce robust reductions in HbA1c with minimal risk of hypoglycemia mainly in insulin-independent settings. Thus, this mechanism of action does present therapeutic advantages that are different from those of the existing glucose-lowering agents and can add on therapeutic benefits when used in combination regimens, especially in those with complex glycemic characteristics or insulin resistance.

Weight reduction through SGLT inhibitors is clinically meaningful, and mechanisms beyond energy loss through glucose excreted in the urine may be in play. Through modulation of gut hormone secretion (GLP-1, PYY) and insulin reduction, primarily insulin administered as exogenous insulin therapy, SGLT-1 inhibitors may aid in the long-term decreases of body weight and fat mass. This becomes vital since there is a bidirectional link between obesity and type 2 diabetes and a growing emphasis that weight loss is a bedrock of disease remission strategies.

Clinically, the implications are substantial. SGLT-1 inhibitors may play a pivotal role in individualized diabetes treatment plans, especially for:

- Patients with postprandial hyperglycemia not adequately addressed by basal insulin or metformin.
- Individuals who are overweight or obese, and need both glycemic and weight interventions.
- Patients with renal impairment or cardiovascular risk, where dual-inhibitor outcomes data (e.g., from SCORED and SOLOIST-WHF trials) suggest extended benefits.

However, limitations still shroud this emerging therapeutic class. There are safety concerns, mainly gastrointestinal discomfort, volume depletion, and diabetic ketoacidosis (DKA)-the patient should be in insulin deficiency conditions-to warrant thoughtful patient selection and frequent monitoring. Then again, much if not all current evidence level stems from that of dual inhibitors, and long-term data on selective SGLT-1 blockade is still lacking.

As the field moves forward, several key research priorities emerge:

- Development and testing of selective SGLT-1 inhibitors, with improved GI tolerability.
- Long-term outcome trials focused on cardiovascular, renal, and mortality endpoints.
- Exploration of microbiome-mediated effects, insulin sensitivity enhancement, and use in non-diabetic populations with obesity or metabolic syndrome.
- Comparative effectiveness research against other weight-centric therapies, including GLP-1 receptor agonists and newer dual-agonist peptides.

In conclusion, SGLT-1 inhibition holds the potential to transform diabetes care, not as a monotherapy but as a strategic component of comprehensive, individualized treatment plans. With continued research and refinement, these agents may help close critical therapeutic gaps—bridging the divide between glucose lowering, weight reduction, and long-term metabolic protection.

REFERENCES

[1] Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's

assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577-1579.

[2] Hjorth MF, Zohar Y, Hill JO, Astrup A. Personalized dietary management of overweight and obesity based on measures of insulin and glucose. Annu Rev Nutr. 2018;38:245-272.

[3] Fiorentino TV, Suraci E, Arcidiacono GP, et al. Duodenal sodium/glucose cotransporter 1 expression under fasting conditions is associated with Postload hyperglycemia. J Clin Endocrinol Metab. 2017;102:3979-3989.

[4] . Nguyen NQ, Debreceni TL, Bambrick JE, et al. Accelerated intestinal glucose absorption in morbidly obese humans: relationship to glucose transporters, incretin hormones, and glycemia. J Clin Endocrinol Metab. 2015;100:968-976.

[5] Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730-1735.

[6] Buse JB, Garg SK, Rosenstock J, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41:1970-1980.

[7] . Garg SK, Henry RR, Banks P, et al. Effects of Sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377:2337-2348.

[8] Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015;38:431-438.

[9] DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017; 13:11-26.

[10] Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515-531.

[11] Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012;12:230-238.

[12] Vrhovac I, Balen Eror D, Klessen D, et al. Localizations of Na(+)-Dglucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch. 2015;467:1881-1898.

[13] . Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-794.

[14] Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354-356.

[15] Ezcurra M, Reimann F, Gribble FM, Emery E. Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol. 2013;13: 922-927.

[16] Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012;46: 261-274.

[17] Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012; 344:d7771.

[18] . Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158-169

[19] Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodiumdependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219-1227.

[20] Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with typePharmacol Ther. 2009;85:513-519.

[21] Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagonlike peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250-259.